Roche AG, of Basel, Switzerland, said Rheumatology and Therapy published a study assessing the long-term safety and efficacy of subcutaneous (SC) Actemra (tocilizumab) in patients with rheumatoid arthritis (RA) previously enrolled in the SUMMACTA and BREVACTA trials.